{
    "root": "351bd434-3965-1167-e063-6294a90a1530",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ursodiol",
    "value": "20250514",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "URSADIOL",
            "code": "3D089V7L0K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14555"
        }
    ],
    "indications": {
        "text": "ursodiol capsules indicated patients radiolucent , noncalcified gallbladder stones < 20 mm greatest diameter elective cholecystectomy would undertaken except presence increased surgical risk due systemic disease , advanced age , idiosyncratic reaction general anesthesia , patients refuse surgery . safety ursodiol capsules beyond 24 months established . ursodiol capsules indicated prevention gallstone formation obese patients experiencing rapid weight loss .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "gallstone dissolution recommended dose ursodiol capsules treatment radiolucent gallbladder stones 8 - 10 mg/kg/day given 2 3 divided doses . ultrasound images gallbladder obtained 6-month intervals first year ursodiol capsules therapy monitor gallstone response . gallstones appear dissolved , ursodiol capsules therapy continued dissolution confirmed repeat ultrasound examination within 1 3 months . patients eventually achieve complete stone dissolution show partial complete dissolution first on-treatment reevaluation . partial stone dissolution seen 12 months ursodiol capsules therapy , likelihood success greatly reduced . gallstone prevention recommended ursodiol capsules gallstone prevention patients undergoing rapid weight loss 600 mg/day ( 300 mg b.i.d . ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ursodiol capsules , usp pink opaque cap , white opaque body black imprint \u201c k237 \u201d cap body containing white off-white powder . bottles 100 supplied child-resistant closures . ( ndc 10702-237-01 ) store 20 25\u00b0c ( 68 77\u00b0f ) ; excursions permitted within 15 oto 30 oc ( 59 oto 86 ) . [ usp controlled room temperature ] . dispense tight container ( usp ) . keep reach children . medical inquiries contact : kvk-tech , inc. customer service 1-215-579-1842 manufactured : kvk-tech , inc. 110 terry drive newtown pa 18940 manufacturer \u2019 code : 10702 item id # : 6318/03 rev . : 04/2024",
    "adverseReactions": "ursodiol capsules dissolve calcified cholesterol stones , radiopaque stones , radiolucent bile pigment stones . hence , patients stones candidates ursodiol capsules therapy . patients compelling reasons cholecystectomy including unremitting acute cholecystitis , cholangitis , biliary obstruction , gallstone pancreatitis , biliary-gastrointestinal fistula candidates ursodiol capsules therapy . allergy bile acids .",
    "indications_original": "Ursodiol Capsules are indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol capsules beyond 24 months is not established.\n                     Ursodiol capsules are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss.",
    "contraindications_original": "Gallstone Dissolution\n                       \u00a0The recommended dose for ursodiol capsules treatment of radiolucent gallbladder stones is 8 - 10 mg/kg/day given in 2 or 3 divided doses.\n\n \n                  Ultrasound images of the gallbladder should be obtained at 6-month intervals for the first year of ursodiol capsules therapy to monitor gallstone response. If gallstones appear to have dissolved, ursodiol capsules therapy should be continued and dissolution confirmed on a repeat ultrasound examination within 1 to 3 months. Most patients who eventually achieve complete stone dissolution will show partial or complete dissolution at the first on-treatment reevaluation. If partial stone dissolution is not seen by 12 months of Ursodiol capsules therapy, the likelihood of success is greatly reduced.\n                  \n                     Gallstone Prevention\n                       The recommended dosage of ursodiol capsules for gallstone prevention in patients undergoing rapid weight loss is 600 mg/day (300 mg b.i.d.).",
    "warningsAndPrecautions_original": "Ursodiol Capsules, USP are pink opaque cap, white opaque body with black imprint \u201cK237\u201d on both cap and body containing white to off-white powder.\n                  Bottles of 100 are supplied with child-resistant closures.\n                  \n                     (NDC 10702-237-01)\n                  \n                  Store at 20 to 25\u00b0C (68 to 77\u00b0F); excursions permitted within 15\n \n  oto 30\n \n  oC (59\n \n  oto 86\n \n  oF). [see USP Controlled Room Temperature].\n\n \n                  Dispense in tight container (USP).\n                  \n                     Keep out of reach of children.\n                  \n                  \n                  For all medical inquiries contact:\n                  KVK-Tech, Inc. Customer Service \n  \n                       1-215-579-1842\n \n                  \n                  Manufactured by: \n  \n                       KVK-Tech, Inc. \n  \n                       110 Terry Drive \n  \n                       Newtown PA 18940\n \n                  \n                     \n                  \n                  Manufacturer\u2019s code: 10702\n                  Item ID #: 6318/03 Rev.: 04/2024",
    "adverseReactions_original": "Ursodiol capsules will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones. Hence, patients with such stones are not candidates for ursodiol capsules therapy.\n                     Patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for ursodiol capsules therapy.\n                     Allergy to bile acids.",
    "drug": [
        {
            "name": "Ursodiol",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14555"
        }
    ]
}